Establishment of a Cleavage-Based Single-Plasmid Dual-Luciferase Surrogate Reporter for the Cleavage Efficiency Evaluation of CRISPR-Cas12a Systems and Its Primary Application
The CRISPR Journal · 2024
DOI: 10.1089/crispr.2024.0038 ↗Kurz gefasst
Fachartikel in der Zeitschrift The CRISPR Journal, 2024. Verfasst von Yaoqiang Shi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Provincial Key Laboratory for Transfusion-Transmitted Infectious Diseases, Institute of Blood Transfusion, Chinese Academy of Medical Sciences and Pe…. Hauptthemen laut MEDLINE: CRISPR-Cas Systems, Gene Editing, RNA, Guide, CRISPR-Cas Systems, Plasmids. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben.
Abstract (Originalsprache)
CRISPR-Cas technology is a widely utilized gene-editing tool that involves gRNA-guided sequence recognition and Cas nuclease-mediated cleavage. The design and evaluation of gRNA are essential for enhancing CRISPR/Cas editing efficiency. Various assays such as single-strand annealing, in vitro cleavage, and T7 endonuclease I (T7EI) are commonly used to assess gRNA-mediated Cas protein cleavage activity. In this study, a firefly luciferase and Renilla luciferase co-expressed and a cleavage-based single-plasmid dual-luciferase surrogate reporter was built to evaluate the gRNA-mediated Cas12a cleavage efficiency. The cleavage activities of CRISPR-Cas12a can be quantitatively determined by the recovery degree of firefly luciferase activity. The cleavage efficiency of CRISPR-Cas12a can be quantitatively measured by the recovery of firefly luciferase activity. By using this system, the cleavage efficiency of CRISPR-Cas12a on hepatitis B virus (HBV)/D expression plasmid was evaluated, revealing a negative correlation between gRNA cleavage efficiency and HBV gene expression measured using an enzyme-linked immunosorbent assay. This simple, efficient, and quantifiable system only requires the dual-luciferase vector and CRISPR-Cas12a vector, making it a valuable tool for selecting effective gRNAs for gene editing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Provincial Key Laboratory for Transfusion-Transmitted Infectious Diseases, Institute of Blood Transfusion, Chinese Academy of Medical Sciences and Peking Union Medical College, Chengdu, China.
- The Joint Laboratory on Transfusion-Transmitted Diseases (TTDs) Between Institute of Blood Transfusion, Chinese Academy of Medical Sciences and Nanning Blood Center, Nanning Blood Center, Nanning, China.
- The Hospital of Xidian Group, Xi'an, China.
ORCID-Profile: Yaoqiang Shi
Zitieren
APA
Shi, Y., Tan, Q., Yang, C., Li, S., Li, Y., He, B., Xie, H., Duan, X., & Chen, L. (2024). Establishment of a Cleavage-Based Single-Plasmid Dual-Luciferase Surrogate Reporter for the Cleavage Efficiency Evaluation of CRISPR-Cas12a Systems and Its Primary Application. The CRISPR Journal. https://doi.org/10.1089/crispr.2024.0038
Vancouver
Shi Y, Tan Q, Yang C, Li S, Li Y, He B, et al. Establishment of a Cleavage-Based Single-Plasmid Dual-Luciferase Surrogate Reporter for the Cleavage Efficiency Evaluation of CRISPR-Cas12a Systems and Its Primary Application. The CRISPR Journal. 2024. doi:10.1089/crispr.2024.0038
BibTeX
@article{Shi2024,
author = {Shi, Yaoqiang and Tan, Qi and Yang, Chunhui and Li, Shilin and Li, Yujia and He, Baoren and Xie, He and Duan, Xiaoqiong and Chen, Limin},
title = {Establishment of a Cleavage-Based Single-Plasmid Dual-Luciferase Surrogate Reporter for the Cleavage Efficiency Evaluation of CRISPR-Cas12a Systems and Its Primary Application},
journal = {The CRISPR Journal},
year = {2024},
doi = {10.1089/crispr.2024.0038}
}
EUVIMED